Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters

Biomedicine and Pharmacotherapy

Volumn 63, Issue 10, 2009, Pages 781-786

  Hirata, Yoichiro ^a,b   Soeki, Takeshi ^a   Akaike, Masashi ^a   Sakai, Yoshiki ^c   Igarashi, Takashi ^b   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Cardiomyopathy; Hamster; Hepatocyte growth factor; Prostacyclin

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; CARDIOVASCULAR AGENT; POLYGLACTIN; PROSTACYCLIN AGONIST; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; HAMSTER; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLOW RELEASE FORMULATION; SYRIAN HAMSTER;

ANIMALS; CARDIOMYOPATHY, DILATED; CRICETINAE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENZYME INHIBITORS; FIBROSIS; LACTIC ACID; MALE; MYOCARDIUM; POLYGLYCOLIC ACID; PYRIDINES; THROMBOXANE-A SYNTHASE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 71749116221     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.09.003     Document Type: Article

References (33)

1. Hunter J.J., and Chien K.R. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341 (1999) 1276-1283
2. Chien K.R. Genomic circuits and the integrative biology of cardiac diseases. Nature 407 (2000) 227-232
3. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79 (1999) 215-262
4. Imawaka H., and Sugiyama Y. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. J Pharmacol Exp Ther 284 (1998) 949-957
5. Hayashi K., Nagamatsu T., Oka T., and Suzuki Y. Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J Pharmacol 73 (1997) 73-82
6. Rudd J.A., Qian Y., Tsui K.K., and Jones R.L. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br J Pharmacol 129 (2000) 782-790
7. Murakami S., Nagaya N., Itoh T., Kataoka M., Iwase T., Horio T., et al. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 290 (2006) L59-L65
8. Nakamura K., Sata M., Iwata H., Sakai Y., Hirata Y., Kugiyama K., et al. A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (London) 112 (2007) 607-616
9. Iwata H., Nakamura K., Sumi M., Ninomiya M., Sakai Y., Hirata Y., et al. Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci 85 (2009) 255-261
10. Sakamoto A., Ono K., Abe M., Jasmin G., Eki T., Murakami Y., et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci U S A 94 (1997) 13873-13878
11. Nakamura T., Nawa K., and Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122 (1984) 1450-1459
12. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342 (1989) 440-443
13. Aoki M., Morishita R., Taniyama Y., Kida I., Moriguchi A., Matsumoto K., et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7 (2000) 417-427
14. Bussolino F., Di Renzo M.F., Ziche M., Bocchietto E., Olivero M., Naldini L., et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119 (1992) 629-641
15. Van Belle E., Witzenbichler B., Chen D., Silver M., Chang L., Schwall R., et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97 (1998) 381-390
16. Balkovetz D.F., and Lipschutz J.H. Hepatocyte growth factor and the kidney: it is not just for the liver. Int Rev Cytol 186 (1999) 225-260
17. Matsumoto K., and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59 (2001) 2023-2038
18. Matsuda Y., Matsumoto K., Ichida T., and Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem 118 (1995) 643-649
19. Ueki T., Kaneda Y., Tsutsui H., Nakanishi K., Sawa Y., Morishita R., et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5 (1999) 226-230
20. Yaekashiwa M., Nakayama S., Ohnuma K., Sakai T., Abe T., Satoh K., et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 156 (1997) 1937-1944
21. Kondo I., Ohmori K., Oshita A., Takeuchi H., Fuke S., Shinomiya K., et al. Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction. J Am Coll Cardiol 44 (2004) 644-653
22. Nakamura T., Matsumoto K., Mizuno S., Sawa Y., and Matsuda H. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 288 (2005) H2131-H2139
23. Matsumoto K., Okazaki H., and Nakamura T. Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. J Biochem 117 (1995) 458-464
24. Johnson III G., Furlan L.E., Aoki N., and Lefer A.M. Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 66 (1990) 1362-1370
25. Coker S.J., Parratt J.R., Ledingham I.M., and Zeitlin I.J. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291 (1981) 323-324
26. Kaneshige T., Saida Y., Tanaka R., Soda A., Fukushima A., Ida N., et al. Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in dahl rats. J Vet Med Sci 69 (2007) 1271-1276
27. Neilan T.G., Jassal D.S., Scully M.F., Chen G., Deflandre C., McAllister H., et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J 27 (2006) 1251-1256
28. Sinzinger H., O'Grady J., and Rogatti W. Long-term improvement in left ventricular ejection fraction during continuous PGE1-therapy in a patient with congestive cardiomyopathy. Postgrad Med J 64 (1988) 975
29. Matsunaga T., Gohda E., Takebe T., Wu Y.L., Iwao M., Kataoka H., et al. Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway. Exp Cell Res 210 (1994) 326-335
30. Nakano N., Morishita R., Moriguchi A., Nakamura Y., Hayashi S.I., Aoki M., et al. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 32 (1998) 444-451
31. Xin X., Yang S., Ingle G., Zlot C., Rangell L., Kowalski J., et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158 (2001) 1111-1120
32. Gille J., Khalik M., Konig V., and Kaufmann R. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J Invest Dermatol 111 (1998) 1160-1165
33. Sakurai S., Alam S., Pagan-Mercado G., Hickman F., Tsai J.Y., Zelenka P., et al. Retinal capillary pericyte proliferation and c-Fos mRNA induction by prostaglandin D2 through the cAMP response element. Invest Ophthalmol Vis Sci 43 (2002) 2774-2781